glp-1 vision loss drugs are associated with a 35% higher risk of NAION, an eye condition that can cause sudden loss. About 6 to 10 extra cases per 10,000 users over 3 years GLP-1 Drugs and Risk for
Description
They affect glucose control through four main mechanisms: Improving insulin secretion: Insulin is released from the pancreas when eating to help blood glucose levels stay stable

This leads to less fat being absorbed and more energy being burned, which may explain part of GLP-1s effectiveness in supporting weight management (Singh et al, 2024)

I am using 250 g (thats micrograms , equivalent to 0.25 mg, a fraction of that 2.5 mg starting dose)

With clear expectations- the natural approach is practical, affordable, and appropriate for a large proportion of urban Indian adults managing metabolic concerns

Exenatide The FDA OKd exenatide in 2005, making it the first approved GLP-1 for Type 2 diabetes
The JPML has established MDL No